said. Stepwise treatment to manage flare-ups depends on patient factors and asthma severity. ... Inhaled combined budesonide-formoterol as needed in mild asthma. N Engl J Med.
Conversely, the presence of asthma in a patient's history can also confound diagnosis. ... Making this particularly tricky, asthma is a risk factor for anaphylaxis and increases the risk of death from an allergic reaction, especially in teens.
Somehow [patients are] supposed to end up in a box describing their asthma severity. ... Another categorization challenge is whether severity should change if asthma improves with treatment.
In 2007, an estimated 3.8 million children suffered an asthma attack or episode. ... Genome-wide association studies are also being employed to unravel the pharmacogenomics of asthma drug responsiveness.
The new insulin inhaler is much more subtle, more like an asthma inhaler, Dr. ... It's also contraindicated in patients with chronic obstructive pulmonary disease or asthma.
It is still unknown whether the better asthma therapies in use today will reduce this risk, he added. ... Another solution to the challenge of fine-tuning asthma care was offered by a study of an online self-management program.
risk of severe exacerbation of asthma symptoms, leading to hospitalizations and some deaths. ... LABAs are now contraindicated without the use of an asthma controller medication and should only be used long-term in patients whose asthma cannot be
Little treatments, lots of time best for back pain | Internal Medicine Meeting 2019 News | ACP Internist
catastrophizing, avoiding activities out of fear (of further injury, for example), and having depression, anxiety, obesity, comorbidities such as diabetes, headaches, or asthma, or a physically demanding job, Dr.
A summary of approvals, recalls, warnings and alerts digested by ACP Internist from the Food and Drug Administration's alerts.
serious asthma-related side effects (e.g., hospitalization, intubation, or death) compared to using ICS alone. ... The trials also assessed efficacy and found that using LABA/ICS combination therapy reduced asthma exacerbations compared to using ICS alone